Metformin to reduce weight gain and metabolic disturbance in schizophrenia

摘要

Weight gain and metabolic disturbances (ie, obesity and diabetes) are common side effects of second-generation antipsychotics.1 Pharmacological interventions might be one approach to preventing or reducing these adverse events in individuals with schizophrenia. Since an earlier Cochrane review in 2007 we conducted,2 research has doubled from 18 to 40 randomised controlled trials representing 19 unique interventions and an updated review of the evidence was timely.